Literature DB >> 26063727

Reviving old antibiotics.

Ursula Theuretzbacher1, Françoise Van Bambeke2, Rafael Cantón3, Christian G Giske4, Johan W Mouton5, Roger L Nation6, Mical Paul7, John D Turnidge8, Gunnar Kahlmeter9.   

Abstract

In the face of increasing antimicrobial resistance and the paucity of new antimicrobial agents it has become clear that new antimicrobial strategies are urgently needed. One of these is to revisit old antibiotics to ensure that they are used correctly and to their full potential, as well as to determine whether one or several of them can help alleviate the pressure on more recent agents. Strategies are urgently needed to 're-develop' these drugs using modern standards, integrating new knowledge into regulatory frameworks and communicating the knowledge from the research bench to the bedside. Without a systematic approach to re-developing these old drugs and rigorously testing them according to today's standards, there is a significant risk of doing harm to patients and further increasing multidrug resistance. This paper describes factors to be considered and outlines steps and actions needed to re-develop old antibiotics so that they can be used effectively for the treatment of infections.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26063727     DOI: 10.1093/jac/dkv157

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  32 in total

Review 1.  [Severe pneumonia in the intensive care unit].

Authors:  T Welte
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-05-09       Impact factor: 0.840

2.  Endless Resistance. Endless Antibiotics?

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Medchemcomm       Date:  2015-11-03       Impact factor: 3.597

3.  Management of MRSA-positive eye swabs and the potential advantages of chloramphenicol availability in the United Kingdom.

Authors:  C Croghan; D Lockington
Journal:  Eye (Lond)       Date:  2017-12-01       Impact factor: 3.775

4.  The Polyaminoisoprenyl Potentiator NV716 Revives Old Disused Antibiotics against Intracellular Forms of Infection by Pseudomonas aeruginosa.

Authors:  Gang Wang; Jean-Michel Brunel; Jean-Michel Bolla; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

5.  Febrile illness of bacterial etiology in a public fever hospital in Egypt: High burden of multidrug resistance and WHO priority Gram negative pathogens.

Authors:  Shimaa H Mostafa; Sarra E Saleh; Samira M Hamed; Khaled M Aboshanab
Journal:  Germs       Date:  2022-03-31

6.  Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics.

Authors:  G M L Consoli; G Granata; R Picciotto; A R Blanco; C Geraci; A Marino; A Nostro
Journal:  Medchemcomm       Date:  2017-12-01       Impact factor: 3.597

Review 7.  Fosfomycin and nitrofurantoin: classic antibiotics and perspectives.

Authors:  Cristiane Dos Santos; Lucas Souza Dos Santos; Octávio Luiz Franco
Journal:  J Antibiot (Tokyo)       Date:  2021-07-09       Impact factor: 2.649

8.  Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in In Vitro Static and Dynamic Models.

Authors:  Wafi Siala; Hector Rodriguez-Villalobos; Prabhavathi Fernandes; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

9.  Semisynthetic Analogues of Anhydrotetracycline as Inhibitors of Tetracycline Destructase Enzymes.

Authors:  Jana L Markley; Luting Fang; Andrew J Gasparrini; Chanez T Symister; Hirdesh Kumar; Niraj H Tolia; Gautam Dantas; Timothy A Wencewicz
Journal:  ACS Infect Dis       Date:  2019-03-05       Impact factor: 5.084

10.  Nitrofurans: Revival of an "old" drug class in the fight against antibiotic resistance.

Authors:  Vuong Van Hung Le; Jasna Rakonjac
Journal:  PLoS Pathog       Date:  2021-07-08       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.